acute myeloid leukemia
Faron reports increased remission rate in trial for myelodysplastic syndrome candidate
August 7, 2025Medical Communications, Research and Development Faron Pharmaceuticals, Oncology, US Food and Drug Administration, acute myeloid leukemia, myelodysplastic syndrome
Faron Pharmaceuticals has reported a rise in complete remission (CR) rates among patients with frontline high-risk myelodysplastic syndrome (HR-MDS) in …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
The evidence bar impacting UK medical cannabis access
November 6, 2026
